Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 5

Sponsor Class

INDUSTRY 5UNKNOWN 2

Study Type

Interventional 5

Sponsor

Conditions

Pain 5Cancer Pain 3Neoplasms 2

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Has results × nabiximols × Clear all
NCT00674609 2023-05-03

SPRAY

Jazz Pharmaceuticals

Phase 3 Completed
177 enrolled 21 charts

Neoplasms, Pain

NCT00675948 2023-05-03

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

Jazz Pharmaceuticals

Phase 3 Completed
43 enrolled 11 charts

Neoplasms, Pain

NCT01337089 2023-04-12

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Jazz Pharmaceuticals

Phase 3 Completed
660 enrolled 9 charts

Cancer Pain, Pain

NCT01361607 2023-04-12

SPRAY III

Jazz Pharmaceuticals

Phase 3 Completed
399 enrolled 17 charts

Cancer Pain, Pain

NCT01424566 2023-04-12

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 3 Completed
406 enrolled 16 charts

Cancer Pain, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡